MRK
Merck & Co., Inc.
OpenVolumeMkt capP/EEPSDiv yield
Day – 52-wk –
Expected move
InputsNext report
Last report
Largest filed tie
13F top-10 QoQ
Top fund weight
Merck has 19 disclosed suppliers and 14 disclosed customers in SEC filings. Named in filings as Merck Sharp & Dohme Corp. (5).
SentenceIn 2025, MSD (tradename of Merck & Co., Inc., Rahway, NJ, USA) licensed Evaxion's vaccine candidate EVX-B3 for a cash payment of $7.5 million, and Evaxion is eligible for future development, regulatory and sales milestone payments as well as royalties on net sales
SentenceThrough December 31, 2025, we have funded our operations with proceeds from our initial public offering ("IPO") in October 2020, sales of preferred stock, term loans, an upfront payment of $15.0 million we received in July 2020 under the Research Collaboration and Exclusive License Agreement (the "Merck Collaboration Agreement") with Merck Sharp & Dohme Corp. ("Merck"), proceeds we received in December 2021 under the Lilly SPA of $80.0 million; an upfront payment of $300.0 million received in January 2022 under the Lilly Collaboration Agreement; a payment of $5.0 million received from Merck under the Merck Collaboration Agreement in the third quarter of 2022 for the achievement of a research milestone; net 70 Table of Contents proceeds of $102.8 million, after deducting underwriting discounts, commissions and other offering expenses, from the May 2024 Offering; and net proceeds from our ATM Facility of $0.5 million.
SentenceAcquired Verona Pharma plc (Verona Pharma), a biopharmaceutical company focused on respiratory diseases, through which Merck obtained Ohtuvayre, a product approved for the maintenance treatment of chronic obstructive pulmonary disease (COPD).
MRK 10-Kaccession 0000310158-26-000063
SentenceAlthough we acquired the exclusive rights to sabirnetug from Merck in 2011 following Merck's strategic decision to focus its AD development efforts on a different product candidate, we did not recommence meaningful operations until we completed our first institutional fundraising in 2018.
SentenceIn July 2021, we entered into clinical collaboration with Merck, a leader in immuno-oncology. The clinical collaboration and supply agreement includes open-label, dose escalation and expansion clinical studies to evaluate our anti-CTLA-4 mAb product candidate, ADG126 in combination with pembrolizumab for patients with advanced/metastatic solid tumors. Under terms of the agreement, Merck provides pembrolizumab and input on our clinical trials evaluating pembrolizumab in combination with ADG126
SentenceIn June 2024, Immutep entered into its third and most important collaboration with Merck & Co., Inc., Rahway, NJ, USA (known as MSD outside the United States and Canada) for the registrational Phase III trial in non-small cell lung cancer called TACTI-004. In addition to working together, MSD was also supplying KEYTRUDA at no cost for the trial.
Sentencewe entered into a supply agreement with Merck to evaluate the combination of INT230-6 with Keytruda ® (pembrolizumab), Merck's anti-PD-1 therapy, in patients with advanced solid malignancies, including pancreatic, bile duct, squamous cell and non-MSI high colon cancers.
SentenceGiven the potential immunobiologic and pharmacodynamic synergy between GPS and an immune check-point inhibitor (e.g., PD-1 inhibitor), we entered into a Clinical Trial Collaboration and Supply Agreement with Merck (known as MSD outside the United States and Canada), to assess the efficacy and safety of GPS in combination with Merck's anti-PD-1 therapy pembrolizumab with exploratory long-term follow-up for OS and safety.
SentenceBeginning in mid-2024, the Company observed a significant decline in shipments from its distributor and commercialization partner in China, Chongqing Zhifei Biological Products Co., Ltd. (Zhifei), to disease and control prevention institutions and correspondingly into the points of vaccination compared with prior quarters of 2024, resulting in above normal inventory levels at Zhifei.
MRK 10-Kaccession 0000310158-26-000063
Last report2 of 8 at or beyond impliedshaded = implied▲▼ = realized× = |realized| ÷ implied
Expected move
No implied move.
+3.83%
vs ±3.4% implied · ×1.11
shaded = implied · ▲▼ = realized
Merck & Co., Inc.
149.66
+3.33 · +2.28%
post 149.47 −0.13%
Linked news